A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Cervical Cancer

Interventions

DRUG

BL-B01D1

BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.

DRUG

SI-B003

SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY